Physician profile
Benjamin Horn
NPI 1124471685
$63,290.72
in general payments reported to CMS, 2019-2025
35 companies · $57K in 2025
The $57K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $91.09 · 2021: $239 · 2022: $564 · 2023: $1,290 · 2024: $3,542 · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Food and Beverage: $8,647 · Consulting Fee: $3,500 · Travel and Lodging: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,731.25 |
| Food and Beverage | $8,646.74 |
| Consulting Fee | $3,500.00 |
| Travel and Lodging | $1,197.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $33,976.53 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $15,076.23 | 2024-2025 | Amvuttra, Onpattro |
| Pfizer INC. | $6,928.00 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $822.58 | 2019-2024 | Farxiga, Brilinta |
| Abiomed | $811.96 | 2023-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $777.52 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $776.28 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $755.95 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $529.79 | 2021-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $357.86 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $300.58 | 2022-2025 | Verquvo, Capvaxive |
| Kiniksa Pharmaceuticals International, Plc | $278.03 | 2024 | Arcalyst |
| Novo Nordisk INC | $272.55 | 2024-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.11 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $182.46 | 2020-2024 | Xarelto |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $145.40 | 2025 | |
| Esperion Therapeutics, INC. | $123.97 | 2023-2025 | Nexletol |
| Daiichi Sankyo INC. | $100.87 | 2023-2024 | Injectafer |
| Medtronic, INC. | $97.15 | 2022-2025 | Corevalve Evolut R |
| Bard Peripheral Vascular, INC. | $93.09 | 2022 | |
| Baxter Healthcare | $72.70 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Glaxosmithkline, LLC. | $70.65 | 2023-2024 | Shingrix, Arexvy |
| Kiniksa Pharmaceuticals, LTD. | $65.53 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $60.22 | 2024 | |
| Lilly USA, LLC | $47.56 | 2025 | Zepbound |
| Boston Scientific Corporation | $46.78 | 2020-2024 | Watchdog |
| Regeneron Healthcare Solutions, INC. | $44.67 | 2025 | Evkeeza |
| Lantheus Medical Imaging, INC. | $42.40 | 2021 | |
| Ge Healthcare | $39.96 | 2022 | |
| Abbott Laboratories | $25.18 | 2023 | Cardiomems |
| Medtronic Vascular, INC. | $25.07 | 2020 | |
| Terumo Medical Corporation | $23.43 | 2025 | Tr Band |
| Edwards Lifesciences Corporation | $19.69 | 2022 | |
| Mannkind Corporation | $16.38 | 2025 | |
| Impulse Dynamics (USA) INC. | $15.59 | 2024 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.